A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity

Vaccine

Volumn 36, Issue 14, 2018, Pages 1846-1852

  Lai, Huafang ^a   Paul, Amber M ^b   Sun, Haiyan ^a   He, Junyun ^a   Yang, Ming ^a   Bai, Fengwei ^b   Chen, Qiang ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b University of Southern Mississippi   (United States)

Author keywords

Antibody dependent enhancement (ADE); Dengue virus (DENV); Domain III (DIII); Envelope protein; Plant made pharmaceuticals; Plant produced vaccine; Vaccine; West Nile virus (WNV); Zika virus (ZIKV)

Indexed keywords

FC RECEPTOR; PLANT PRODUCED WEST NILE ENVELOPE PROTEIN DOMAIN III VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; WEST NILE VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; DENGUE; DRUG POTENCY; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; MOUSE; NICOTIANA BENTHAMIANA; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; SENSITIZATION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; WEST NILE FEVER; ZIKA FEVER; ANIMAL; DENGUE VIRUS; HUMAN; IMMUNOLOGY; SERODIAGNOSIS; WEST NILE VIRUS; ZIKA VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HUMANS; IMMUNOGLOBULIN G; MICE; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85042461138     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2018.02.073     Document Type: Article

References (53)

1. Petersen, L.R., Brault, A.C., Nasci, R.S., West Nile virus: review of the literature. Jama 310 (2013), 308–315.
2. Ye, Q., Liu, Z.-Y., Han, J.-F., Jiang, T., Li, X.-F., Qin, C.-F., Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. Infection, Genet Evol 43 (2016), 43–49.
3. Chang, H.-H., Huber, R.G., Bond, P.J., Grad, Y.H., Camerini, D., Maurer-Stroh, S., et al. Systematic analysis of protein identity between Zika virus and other arthropod-borne viruses. Bull World Health Org 95 (2017), 517–525.
4. Bode, A.V., Sejvar, J.J., Pape, W.J., Campbell, G.L., Marfin, A.A., West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis 42 (2006), 1234–1240.
5. Diamond, M.S., Klein, R.S., A genetic basis for human susceptibility to West Nile virus. Trends Microbiol 14 (2006), 287–289.
6. Hart, J., Tillman, G., Kraut, M.A., Chiang, H.-S., Strain, J.F., Li, Y., et al. West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infectious Diseases, 14, 2014, 248.
7. Bardina, S.V., Bunduc, P., Tripathi, S., Duehr, J., Frere, J.J., Brown, J.A., et al. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356 (2017), 175–180.
8. Morens, D.M., Antibody-dependent of enhancement of infection and the pathogenesis of viral disease. Clin Inf Dis 19 (1994), 500–512.
9. Oliphant, T., Engle, M., Nybakken, G., Doane, C., Johnson, S., Huang, L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11 (2005), 522–530.
10. Belmusto-Worn, V.E., Sanchez, J.L., McCarthy, K., Nichols, R., Bautista, C.T., Magill, A.J., et al. Randomized, double-blind, phase III. Pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (ARILVAX™ and YF-VAX®) in healthy infants and children in Peru. Am J Tropical Med Hygiene 72 (2005), 189–197.
11. Heinz, F.X., Holzmann, H., Essl, A., Kundi, M., Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25 (2007), 7559–7567.
12. Zhao, H., Fernandez, E., Dowd Kimberly, A., Speer Scott, D., Platt Derek, J., Gorman Matthew, J., et al. Structural basis of zika virus-specific antibody protection. Cell 166 (2016), 1016–1027.
13. Alonso-Padilla, J., Jiménez de Oya, N., Blázquez, A.-B., Escribano-Romero, E., Escribano, J.M., Saiz, J.-C., Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease. Vaccine 29 (2011), 1830–1835.
14. Chu, J.J., Rajamanonmani, R., Li, J., Bhuvanakantham, R., Lescar, J., Ng, M.L., Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol 86 (2005), 405–412.
15. He, J., Peng, L., Lai, H., Hurtado, J., Stahnke, J., Chen, Q., A plant-produced antigen elicits potent immune responses against West Nile virus in mice. Biomed Res Int, 2014, 2014, 10.
16. Leuzinger, K., Dent, M., Hurtado, J., Stahnke, J., Lai, H., Zhou, X., et al. Efficient Agroinfiltration of plants for high-level transient expression of recombinant proteins. J Visualized Exp, 2013, 10.3791/50521.
17. Chen Q, Dent M, Hurtado J, Stahnke J, McNulty A, Leuzinger K, et al. Transient Protein Expression by Agroinfiltration in Lettuce. Methods in molecular biology, Clifton, NJ; 2016; 1385: 55–67.
18. Chen Q, Davis K. The potential of plants as a system for the development and production of human biologics F1000Research. 2016; 5. doi: 10.12688/f1000research.8010.1.
19. Chen, Q., Expression and purification of pharmaceutical proteins in plants. Biol Eng 1 (2008), 291–321.
20. Tuse, D., Tu, T., McDonald, K., Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. Biomed Res Int, 2014, 2014, 10.
21. Chen, Q., Lai, H., Gene delivery into plant cells for recombinant protein production. Biomed Res Int, 2014, 2014, 10.
22. Chen Q. Recombinant Therapeutic Molecules Produced in Plants. Advances in Botanical Research, Academic Press; 2018; 86: 207–44. http://doi.org//10.1016/bs.abr.2017.11.006.
23. Lai, H., Engle, M., Fuchs, A., Keller, T., Johnson, S., Gorlatov, S., et al. Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc Natl Acad Sci USA 107 (2010), 2419–2424.
24. Yang, M., Dent, M., Lai, H., Sun, H., Chen, Q., Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vacccine 35 (2017), 4287–4294.
25. Dent, M., Hurtado, J., Paul, A.M., Sun, H., Lai, H., Yang, M., et al. Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J Gen Virol 97 (2016), 3280–3290.
26. Paul, A.M., Shi, Y., Acharya, D., Douglas, J.R., Cooley, A., Anderson, J.F., et al. Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J Gen Virol 95 (2014), 1712–1722.
27. Yang, M., Sun, H., Lai, H., Hurtado, J., Chen, Q., Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice. Plant Biotechnol J, 2017, 10.1111/pbi.12796.
28. Yang, M., Lai, H., Sun, H., Chen, Q., Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci Rep, 7, 2017, 7679.
29. Hombach, J., Solomon, T., Kurane, I., Jacobson, J., Wood, D., Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23 (2005), 5205–5211.
30. Kreil, T.R., Burger, I., Bachmann, M., Fraiss, S., Eibl, M.M., Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 110 (1997), 358–361.
31. Mason, R.A., Tauraso, N.M., Spertzel, R.O., Ginn, R.K., Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25 (1973), 539–544.
32. Larocca, R.A., Abbink, P., Peron, J.P.S., Zanotto PM, de A., Iampietro, M.J., Badamchi-Zadeh, A., et al. Vaccine protection against Zika virus from Brazil. Nature, 536, 2016, 474-478.
33. Crill, W.D., Chang, G.J., Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78 (2004), 13975–13986.
34. Pinto, A.K., A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol, 87, 2013, 1926.
35. Minke, J.M., Siger, L., Karaca, K., Austgen, L., Gordy, P., Bowen, R., et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl, 2004, 221–230.
36. Monath, T.P., Liu, J., Kanesa-Thasan, N., Myers, G.A., Nichols, R., Deary, A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA, 2006.
37. Sun, H., Chen, Q., Lai, H., Development of antibody therapeutics against flaviviruses. Int J Mol Sci, 19, 2018, 54.
38. Martina, B.E., Koraka, P., van den Doel, P., van Amerongen, G., Rimmelzwaan, G.F., Osterhaus, A.D.M.E., Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26 (2008), 153–157.
39. He, J., Lai, H., Engle, M., Gorlatov, S., Gruber, C., Steinkellner, H., et al. Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus. PLoS ONE, 9, 2014, e93541, 10.1371/journal.pone.0093541.
40. Lai, H., He, J., Hurtado, J., Stahnke, J., Fuchs, A., Mehlhop, E., et al. Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants. Plant Biotechnol J 12 (2014), 1098–1107.
41. Vogt, M.R., Moesker, B., Goudsmit, J., Jongeneelen, M., Austin, S.K., Oliphant, T., et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 83 (2009), 6494–6507.
42. Demento, S.L., Bonafe, N., Cui, W., Kaech, S.M., Caplan, M.J., Fikrig, E., et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 185 (2010), 2989–2997.
43. Lindblad, E.B., Aluminium compounds for use in vaccines. Immunol Cell Biol 82 (2004), 497–505.
44. Firbas, C., Jilma, B., Product review on the JE vaccine IXIARO. Human Vacc Immunother 11 (2015), 411–420.
45. Phoolcharoen, W., Dye, J.M., Kilbourne, J., Piensook, K., Pratt, W.D., Arntzen, C.J., et al. A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge. Proc Natl Acad Sci USA 108 (2011), 20695–20700.
46. Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology spectrum 2014; 2.
47. Dejnirattisai, W., Supasa, P., Wongwiwat, W., Rouvinski, A., Barba-Spaeth, G., Duangchinda, T., et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol, 2016 advance online publication.
48. Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., et al. Structural basis of potent Zika–dengue virus antibody cross-neutralization. Nature 536 (2016), 48–53.
49. Stettler, K., Beltramello, M., Espinosa, D.A., Graham, V., Cassotta, A., Bianchi, S., et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science, 353, 2016, 823.
50. Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352 (2016), 467–470.
51. Beltramello, M., Williams, K.L., Simmons, C.P., Macagno, A., Simonelli, L., Quyen Nguyen Than, H., et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8 (2010), 271–283.
52. Lin, H.E., Tsai, W.Y., Liu, I.J., Li, P.C., Liao, M.Y., Tsai, J.J., et al. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis, 6, 2012, e1447.
53. Oliphant, T., Nybakken, G.E., Austin, S.K., Xu, Q., Bramson, J., Loeb, M., et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81 (2007), 11828–11839.